Equities Analysts Set Expectations for TYRA FY2025 Earnings

Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) - Analysts at HC Wainwright lifted their FY2025 earnings estimates for shares of Tyra Biosciences in a research report issued to clients and investors on Monday, May 19th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($2.27) per share for the year, up from their previous estimate of ($2.37). HC Wainwright has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for Tyra Biosciences' current full-year earnings is ($1.57) per share. HC Wainwright also issued estimates for Tyra Biosciences' Q4 2025 earnings at ($0.62) EPS, Q1 2026 earnings at ($0.64) EPS, Q2 2026 earnings at ($0.65) EPS, Q3 2026 earnings at ($0.67) EPS and Q4 2026 earnings at ($0.70) EPS.

A number of other equities research analysts have also recently commented on TYRA. Wedbush reaffirmed an "outperform" rating and issued a $30.00 target price on shares of Tyra Biosciences in a report on Friday, March 28th. Piper Sandler assumed coverage on Tyra Biosciences in a research note on Wednesday, May 21st. They issued an "overweight" rating and a $33.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $30.83.

Tyra Biosciences Stock Down 3.1%

Tyra Biosciences stock traded down $0.30 during mid-day trading on Wednesday, reaching $9.29. 189,305 shares of the company's stock were exchanged, compared to its average volume of 264,666. The company has a market cap of $493.21 million, a P/E ratio of -5.77 and a beta of 1.17. The company has a fifty day moving average of $9.43 and a 200-day moving average of $12.56. Tyra Biosciences has a twelve month low of $6.42 and a twelve month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02.

Institutional Trading of Tyra Biosciences

A number of institutional investors have recently bought and sold shares of the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Tyra Biosciences in the 4th quarter valued at $31,000. US Bancorp DE acquired a new stake in Tyra Biosciences during the fourth quarter worth about $50,000. BNP Paribas Financial Markets acquired a new position in shares of Tyra Biosciences in the fourth quarter valued at $60,000. Aquatic Capital Management LLC bought a new position in Tyra Biosciences during the fourth quarter worth about $64,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Tyra Biosciences in the 1st quarter worth about $84,000. Institutional investors and hedge funds own 84.14% of the company's stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.